Zacks Research Issues Positive Outlook for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Research analysts at Zacks Research boosted their Q2 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a research note issued on Tuesday, February 4th. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will post earnings of $3.77 per share for the quarter, up from their previous estimate of $3.76. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.93) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ FY2025 earnings at $14.98 EPS, Q1 2026 earnings at $3.77 EPS and Q2 2026 earnings at $3.99 EPS.

Several other equities analysts have also commented on the company. HC Wainwright boosted their price target on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $500.00 to $550.00 in a research report on Monday, December 9th. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. dropped their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. Finally, Citigroup started coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $469.32 on Friday. The stock’s 50 day moving average price is $435.84 and its 200 day moving average price is $462.87. The firm has a market capitalization of $120.86 billion, a PE ratio of -235.84, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in Vertex Pharmaceuticals by 0.8% during the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock valued at $5,495,501,000 after purchasing an additional 90,173 shares during the period. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 18.1% during the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock valued at $2,581,373,000 after purchasing an additional 851,054 shares during the period. Wellington Management Group LLP boosted its position in Vertex Pharmaceuticals by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after purchasing an additional 704,421 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Vertex Pharmaceuticals by 5.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after purchasing an additional 159,693 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Vertex Pharmaceuticals by 4.1% during the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock valued at $1,170,506,000 after purchasing an additional 100,114 shares during the period. 90.96% of the stock is currently owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.